NYSE:NVS Investor Alert: Investigation over Possible Securities Laws Violations by Novartis AG

An investigation for investors in Novartis AG (NYSE:NVS) shares over potential securities laws violations by Novartis AG was announced.

Logo

San Diego, CA -- (ReleaseWire) -- 06/17/2022 --Novartis AG is under investigation concerning potential securities laws violations in connection with certain financial statements.

Investors who purchased shares of Novartis AG (NYSE: NVS), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether certain statements by Novartis AG regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Switzerland based Novartis AG researches, develops, manufactures, and markets healthcare products worldwide.

On May 5, 2022, Novartis AG "announced a temporary, voluntary suspension of production at its radioligand therapy production sites in Ivrea, Italy and Millburn, New Jersey." The production halt was to "address potential quality issues identified in its manufacturing process."

Shares of Novartis AG (NYSE: NVS) declined from $88.50 per share on May 4, 2022, to $83.37 per share on May 9, 2022.

Then, on May 31, 2022, an article was published entitled "Documents show problems at Novartis facility where cancer drug production was halted." The article reported that the U.S. Food and Drug Administration had cited deficiencies at the Company's New Jersey facility following an inspection in late 2021, including a "concern that Novartis failed to notify customers about batches of Lutathera . . . that were distributed despite failing to meet quality specifications."

Shares of Novartis AG (NYSE: NVS) declined from $92.12 per share on May 24, 2022, to $80.16 per share during June 14, 2022.

Those who purchased shares of Novartis AG (NYSE: NVS) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Christopher Clausen
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About The Shareholders Foundation
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

Media Relations Contact

Christopher Clausen
Shareholders Foundation
1-858-779-1554
https://www.shareholdersfoundation.com/

View this press release online at: http://rwire.com/1359260